CSBio CSBio

X
[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Launch of a First Generic Version of Revlimid\u00ae (lenalidomide capsules), in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces FDA Approval of APHEXDA\u2122 (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"BioLineRx"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","amount":"$279.6 million","upfrontCash":"$29.6 million","newsHeadline":"BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Peptide","graph2":"BioLineRx"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Pricing of $23 Million Public Offering of Securities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Gamida Cell"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell\u2019s Allogeneic Cell Therapy Omisirge\u00ae (omidubicel-onlv) Receives FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Gamida Cell"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Inks Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK\u00ae in a Multi-Regional Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medison Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Medison Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae (cemiplimab) in Multiple Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Medison Pharma"},{"orgOrder":0,"company":"Padagis","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Doxil\u00ae (Doxorubicin Liposome Injection)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Padagis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Medison will commercialize Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.

            Lead Product(s): Cemiplimab

            Therapeutic Area: Oncology Product Name: Libtayo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.

            Lead Product(s): Motixafortide,G-CSF

            Therapeutic Area: Oncology Product Name: Aphexda

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Gloria Biosciences

            Deal Size: $279.6 million Upfront Cash: $29.6 million

            Deal Type: Licensing Agreement October 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            APHEXDA (motixafortide) is a CXCR4 antagonist , which is investigated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

            Lead Product(s): Motixafortide,G-CSF

            Therapeutic Area: Oncology Product Name: Aphexda

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Gamida Cell intends to use the net proceeds to fund the commercialization activities to support the launch of Omisirge (omidubicel-onlv) and the continued clinical development of GDA-201.

            Lead Product(s): Omidubicel-onlv

            Therapeutic Area: Oncology Product Name: Omisirge

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Piper Sandler & Co.

            Deal Size: $23.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Omisirge (omidubicel-onlv) ,FDA approved, is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy,it is indicated for hematologic malignancies who are planned for umbilical cord blood transplantation.

            Lead Product(s): Omidubicel-onlv

            Therapeutic Area: Oncology Product Name: Omisirge

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.

            Lead Product(s): Tebentafusp-tebn

            Therapeutic Area: Oncology Product Name: Kimmtrak

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Immunocore

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Revlimid (lenalidomide capsules), a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, is first generic version available in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

            Lead Product(s): Lenalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Lenalidomide-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Doxil® Liposome Injection is an anthracycline topoisomerase inhibitor indicated for Ovarian Cancer, AIDS-related Kaposi's Sarcoma and Multiple Myeloma.

            Lead Product(s): Doxorubicin Hydrochloride

            Therapeutic Area: Oncology Product Name: Doxil

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ayana Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).

            Lead Product(s): Ripretinib

            Therapeutic Area: Oncology Product Name: Qinlock

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY